查看文章

Methods

Efgartigimod 10 mg/kg or placebo was administered intravenously in cycles of 4 weekly infusions, with subsequent cycles initiated based on clinical evaluation. Outcome measures included MG-ADL and QMG scores, with responder status defined as≥ 2-(MG-ADL) and≥ 3-point (QMG) improvements for≥ 4 consecutive weeks, with first improvement occuring≤ 1 week after last infusion. This analysis assessed baseline characteristics and response in AChR-Ab+ patients who had previously failed therapies for gMG.

Results

Among 81 AChR-Ab+ patients with prior treatment failures included in ADAPT, baseline characteristics were balanced, with mean (SD) MG-ADL scores of 9.2 (1.95) for efgartigimod-treated patients and 8.8 (1.69) for placebo-treated patients (Table 1). More efgartigimod-treated patients (67.5%, n= 27/40) were MG-ADL responders compared to placebo-treated patients (31.7%, n= 13/41; P …